Jefferies Group set a CHF 300 price target on Roche (VTX:ROG) in a report published on Friday, January 5th. The firm currently has a buy rating on the healthcare company’s stock.
A number of other research firms have also recently commented on ROG. Credit Suisse Group set a CHF 260 price target on shares of Roche and gave the stock a neutral rating in a research note on Monday, October 16th. Baader Bank set a CHF 231 price objective on shares of Roche and gave the company a neutral rating in a research report on Thursday, October 19th. Morgan Stanley set a CHF 260 price objective on shares of Roche and gave the company a neutral rating in a research report on Friday, December 8th. Goldman Sachs Group set a CHF 325 price objective on shares of Roche and gave the company a buy rating in a research report on Monday, October 2nd. Finally, set a CHF 210 price target on shares of Roche and gave the stock a sell rating in a research report on Monday, September 18th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of CHF 258.95.
Shares of Roche (ROG) traded down CHF 2.50 during midday trading on Friday, reaching CHF 229.45. 2,790,000 shares of the company’s stock were exchanged, compared to its average volume of 1,620,000. Roche has a one year low of CHF 226.10 and a one year high of CHF 273. The company has a market cap of $197,780.00 and a P/E ratio of 20.40.
TRADEMARK VIOLATION WARNING: “Roche (VTX:ROG) PT Set at CHF 300 by Jefferies Group” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/31/roche-rog-given-a-chf-300-price-target-at-jefferies-group.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.